Amgen

From Wikipedia, the free encyclopedia

Template:Short description Template:DMCA

Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.

Amgen Inc.
FormerlyApplied Molecular Genetics (1980–1983)
Company type
Public
Page Template:Plainlist/styles.css has no content.
ISINScript error: No such module "WikidataIB".
IndustryScript error: No such module "WikidataIB".
PredecessorScript error: No such module "WikidataIB".
IncorporatedScript error: No such module "WikidataIB".
FoundedScript error: No such module "WikidataIB".
FounderScript error: No such module "WikidataIB".
DefunctScript error: No such module "WikidataIB".
SuccessorScript error: No such module "WikidataIB".
HeadquartersThousand Oaks, California, U.S.
Key people
Page Template:Plainlist/styles.css has no content.
ProductsPage Template:Hlist/styles.css has no content.
RevenueScript error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Total assetsScript error: No such module "WikidataIB".
Total equityIncrease Template:US$ (2025)
Number of employees
Script error: No such module "WikidataIB".
ParentScript error: No such module "WikidataIB".
Websiteamgen.com
Footnotes / references
[1]

Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

The company's major products are Prolia and XGEVA (denosumab) to treat osteoporosis and bone diseases ($6.6 billion in total 2025 revenues), Repatha (evolocumab) to treat hyperlipidemia ($3.0 billion in 2025 revenues), Otezla (apremilast) to treat psoriasis and psoriatic arthritis ($2.3 billion in 2025 revenues), Enbrel (etanercept) to treat autoimmune diseases ($2.2 billion in 2025 revenues), Evenity (romosozumab) to treat osteoporosis ($2.1 billion in 2025 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.9 billion in 2025 revenues), Blincyto (blinatumomab) to treat acute lymphoblastic leukemia ($1.6 billion in 2025 revenues), Nplate (romiplostim) to regulate platelet production ($1.5 billion in 2025 revenues), Tezspire (tezepelumab) to treat asthma ($1.5 billion in 2025 revenues), Kyprolis (carfilzomib) to treat cancer ($1.4 billion in 2025 revenues), Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.4 billion in 2025 revenues), Krystexxa (pegloticase) to treat gout ($1.3 billion in 2025 revenues), and Vectibix (panitumumab), a monoclonal antibody ($1.2 billion in 2025 revenues).[1]

Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.[2]

The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.[1]

The company is ranked 134th on the Fortune 500[3] and 202nd on the Forbes Global 2000.[4]

In 2020, the company was added to the Dow Jones Industrial Average (DJIA).[5]

History

File:AMGenelogo.jpg
AMGen corporate logo, 1983
Argentine president Mauricio Macri meets with heads of Amgen, in 2018.

In April 1980, Amgen was founded in Thousand Oaks as Applied Molecular Genetics.[6] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin.[7]

Winston Salser, a molecular biologist at UCLA recruited its initial scientific advisory board consisting of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.[8] In October 1980, Amgen named George Rathmann its first president and chief executive officer.[7][9]

On June 17, 1983, Amgen became a public company via an initial public offering, selling two million common shares and raising nearly $40 million.[10][11][12] That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin found and cloned the erythropoietin gene, a protein created in the kidney that stimulates red blood cell production. Lin's team created what would become Epogen (epoetin alfa).[13][14]

In June 1984, Amgen and Kirin Brewery Company formed a joint venture giving Kirin the rights to Epogen in Japan, while Amgen retained United States distribution rights; both companies had the opportunity to expand to other countries.[15] This joint venture gave way in 2017 to a new joint venture, Kirin-Amgen, which bought out Kirin Holdings stake.[16] A year later, Amgen researcher Larry Souza and his team cloned granulocyte colony-stimulating factor (G-CSF), leading to the development of Neupogen (filgrastim).[14][17][18]

In October 1988, Gordon Binder was named CEO, succeeding George Rathmann.[19] The following year, in 1989, Amgen received approval for the first recombinant human erythropoetin product, Epogen (epoetin alfa).[20]

In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[21]

Amgen opened a new manufacturing facility in Puerto Rico, in March 1993, which later became the company's flagship manufacturing site.[22]

In 1994, Amgen became the fifth company to receive the National Medal of Technology and Innovation from the United States Department of Commerce, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients.[23] Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp (darbepoetin alfa).[24]

2000–2014

Binder was succeeded as CEO by Kevin W. Sharer in 2000.[25] Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement.[26]

In June 2010, Amgen received approval by the Food and Drug Administration for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[27] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[28] In November 2010, the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[29] The clinical trials primarily enrolled patients with breast or prostate cancer.

In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland.[30]

Amgen opened an affiliate in China in 2013.[31][32]

In November 2014, the company halted all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[33] Also in November 2014, the company, in conjunction with AstraZeneca, reported positive results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[34] In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore.[35] Blincyto (blinatumomab) was approved by the FDA in December of that year.[36][37]

2015–2020

In March 2015, the company announced that it would license its Phase II candidate drug AMG 714 to Celimmune, which will develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[38] In August 2015, Repatha (evolocumab) was approved by the FDA.[39]

In September 2016, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.[40] Also in September, the FDA approved Amjevita (adalimumab-atto).[41] The FDA approved Parsabiv in February 2017[42] and Mvasi (bevacizumab-awwb) in September.[43]

In July 2018, Amgen began constructing a biomanufacturing plant at its campus in West Greenwich, Rhode Island.[44][45]

In January 2019, Evenity (romosozumab) received approval in Japan,[46][47] followed by FDA approval in April.[48] In June, Kanjinti (trastuzumab-anns) was approved by the FDA.[49]

In December 2019, the FDA approved Avsola (infliximab-axxq).[50]

In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation.[51]

In April 2020, Amgen established Amgen K.K. as the company's wholly owned affiliate in Japan.[52][53] The company announced in July that the United States Court of Appeals for the Federal Circuit had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the United States District Court for the District of New Jersey and rejected Sandoz's attempt to invalidate the patents on Enbrel.[54]

In August 2020, Amgen, Takeda Pharmaceutical Company, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen.[55]

In September 2020, Amgen and Eli Lilly and Company announced a global manufacturing collaboration for COVID-19 antibody therapies.[56]

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy).[57] Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19.[58]

In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19.[59] Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.[60] Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma.[61]

In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation.[62] Also in December 2020, the FDA approved Riabni (rituximab-arrx), a biosimilar to Rituxan.[63][64]

In April 2021, the company acquired Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion.[65][66][67][68]

In the March 2021, Amgen acquired Rodeo Therapeutics for $720 million.[69][70]

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation.[71] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe[72] and Japan.[73] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.[74]

In June 2021, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for atopic dermatitis.[75] In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.[76][77] Amgen began construction on a new biomanufacturing plant in New Albany, Ohio, in November.[78] In December, the FDA approved Amgen and AstraZeneca's Tezspire (tezepelumab) for severe asthma.[79] The FDA also approved Amgen's Otezla for adults with plaque psoriasis of any severity level.[80]

Amgen announced a research collaboration in January 2022 with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.[81][82] The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics.[83][84] The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.[85][86] Also in February, Amgen issued its first green bond to fund various environmentally friendly initiatives across the company.[87][88] The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March.[89][90]

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras (sotorasib) beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers. The drug was approved in 2021 with a list price of $17,900 per month.[91]

In October 2022, the company acquired ChemoCentryx, the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated vasculitis, for $3.7 billion in an all-cash deal.[92][93][94]

In October 2023, Amgen acquired Horizon Therapeutics, specializing in drugs for rare diseases, for $27.8 billion.[95][96]

In November 2023, Amgen announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines and use the Amazon SageMaker machine learning service to help with the manufacturing process.[97]

In March 2025, data for the drug Tezspire (tezepelumab), showed the best results for treating chronic rhinosinusitis with nasal polyps.[98]

Also in March 2025, Amgen announced the start of two late-stage trials for MariTide, an anti-obesity medication candidate.[99][100] In June 2025, the company noted that it had to reduce the dosage of the drug to avoid side effects such as vomiting.[101] However, patients that continued to take the drug lost approximately 20% of their body weight.[102]

In April 2025, the company announced a $900 million expansion of its facility in New Albany, Ohio.[103] In September 2025, it announced plans to build a $600 million research center in Thousand Oaks, California.[104]

Acquisition history

Page Template:Hidden begin/styles.css has no content.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Page Template:Tree list/styles.css has no content.
  • Amgen Inc. (Founded 1983 as Applied Molecular Genetics)
    • Synergen Inc (Acq 1994)[105]
    • Kinetix Pharmaceuticals Inc (Acq 2000)[106]
    • Immunex Corporation (Acq 2002)
    • Tularik Inc (Acq 2004)
    • Abgenix Inc (Acq 2006)
    • Avidia Inc (Acq 2006)[107]
    • Alantos Pharmaceuticals (Acq 2007)[108]
    • Ilypsa Inc (Acq 2007)[109]
    • BioVex Group Inc (Acq 2011)
    • Micromet Inc (Acq 2012)
    • Mustafa Nevzat İlaç (Acq 2012)
    • KAI Pharmaceuticals (Acq 2012)
    • deCODE genetics (Acq 2012)
    • Onyx Pharmaceuticals (Acq 2013)
    • NextCODE genetics (Spun off 2013)
    • Dezima Pharma (Acq 2015)
    • Catherex (Acq 2015)[110]
    • Nuevolution AB (Acq 2019)
    • Otezla (apremilast) (Acq 2019)[111]
    • Five Prime Therapeutics (Acq 2021)[112]
    • Rodeo Therapeutics Corporation (Acq 2021)[113]
    • Teneobio (Acq 2021)
    • ChemoCentryx (Acq 2022)[114]
    • Horizon Therapeutics (Acq 2023)
      • Vidara Therapeutics International (Acq 2014)
      • Hyperion Therapeutics (Acq 2015)
      • Crealta Holdings (Acq 2015)
      • Raptor Pharmaceutical (Acq 2016)
      • River Vision Development Corp. (Acq 2017)
      • Viela Bio Inc (Acq 2021)[115]

Corporate affairs

Sponsorships

In December 2023, Amgen became the title sponsor of the Irish Open in golf, renaming it the Amgen Irish Open.[116]

Philanthropy

In October 2017, the Amgen Foundation pledged $3 million to Khan Academy to support the development of free online biology lessons.[117][118] In July 2020, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning.[119][120]

In January 2020, the Amgen Foundation and Harvard University debuted LabXchange, a free online science education platform.[121][122] Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.[123]

In November 2021, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for cancer treatments.[124]

Products

Amgen's approved drugs or therapeutic biologicals include:

Products developed and then sold

In December 2012, Amgen plead guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints regarding the improper marketing of anemia drug Aranesp. According to the United States Department of Justice, Amgen sold the drug for off-label uses at dosages that the FDA had rejected or never approved.[137][138]

In May 2025, a jury awarded Regeneron $406 million from Amgen, which engaged in anticompetitive practices to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's Praluent.[139]

See also

Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c Page Module:Citation/CS1/styles.css has no content."2025 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 13, 2026.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Pipeline". Amgen Pipeline.
  3. ^ Page Module:Citation/CS1/styles.css has no content."Fortune: Amgen". Fortune.
  4. ^ Page Module:Citation/CS1/styles.css has no content."Forbes: Amgen". Forbes.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Salesforce.com, Amgen and Honeywell International Set to Join Dow Jones Industrial Average". News Release Archive. Retrieved January 21, 2026.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Costello, Daniel (August 9, 2007). "Amgen's troubles loom large over hometown". Los Angeles Times.
  7. ^ a b Page Module:Citation/CS1/styles.css has no content.Walsh, Robin (October 27, 2010). "A history of: Amgen". pharmaphorum.com.
  8. ^ Page Module:Citation/CS1/styles.css has no content."George Rathmann 1927–2012". Nature Biotechnology. 30 (6): 481. June 7, 2012. doi:10.1038/nbt0612-481.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Pollack, Andrew (April 24, 2012). "George Rathmann, Amgen Chief, Dies at 84". The New York Times.
  10. ^ Page Module:Citation/CS1/styles.css has no content."Small Company Initial Public Offerings: June 1983". Inc. September 1, 1983.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Ward, Nicholas (April 21, 2019). "Amgen: This Beaten Down Blue Chip Is Priced To Own". TheStreet.com.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Timmerman, Luke (May 13, 2002). "Shrewd science: Biotech giant Amgen's success reflects its savvy corporate style". The Seattle Times.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Bate, James (June 2, 1989). "Biotech Detective Scores Coup : Amgen scientist spent years searching for the key to producing EPO". Los Angeles Times.
  14. ^ a b Page Module:Citation/CS1/styles.css has no content.Kim, Rachel (2019). Economics and management in the biopharmaceutical industry in the USA: evolution and strategic change. London: Routledge. pp. 2002–2003. ISBN 9781351012690.
  15. ^ Page Module:Citation/CS1/styles.css has no content."Kirin and Amgen Hormone Venture". The New York Times. Reuters. June 15, 1984. Archived from the original on May 24, 2015.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Japan's Kirin cashes out of Amgen drug joint venture". Reuters. October 31, 2017.
  17. ^ Page Module:Citation/CS1/styles.css has no content.Murphy, Barbara (May 20, 1997). "Souza to Run Research at Biotech King Amgen". Los Angeles Times.
  18. ^ Page Module:Citation/CS1/styles.css has no content.Bendall, Linda J.; Bradstock, Kenneth F. (August 2014). "G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent". Cytokine & Growth Factor Reviews. 25 (4): 355–367. doi:10.1016/j.cytogfr.2014.07.011. PMID 25131807.
  19. ^ Page Module:Citation/CS1/styles.css has no content."Gordon M. Binder, chief executive of Amgen..." Los Angeles Times. October 17, 1995.
  20. ^ Page Module:Citation/CS1/styles.css has no content."Amgen and its erythropoietin drugs". The Washington Post. July 19, 2012.
  21. ^ Page Module:Citation/CS1/styles.css has no content.Pollack, Andrew (February 22, 1991). "An F.D.A. Approval for Amgen". The New York Times. ISSN 0362-4331.
  22. ^ Page Module:Citation/CS1/styles.css has no content.Apodaca, Patrice (August 17, 1993). "Amgen to Open Puerto Rico Plant Despite Tax Credit Cut : Biotechnology: Analysts say the benefit reduction does not alter expectations of strong long-term growth for the Thousand Oaks giant". Los Angeles Times.
  23. ^ Page Module:Citation/CS1/styles.css has no content.Nathans, Aaron (September 16, 1994). "Amgen, Phone Entrepreneur Win Medal of Technology". Los Angeles Times.
  24. ^ Page Module:Citation/CS1/styles.css has no content."A Biotech Wonder Grows Up". Forbes. September 3, 2001.
  25. ^ Page Module:Citation/CS1/styles.css has no content."Amgen names new CEO". CNN. May 11, 2000. Archived from the original on December 20, 2002.
  26. ^ Page Module:Citation/CS1/styles.css has no content."Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012" (Press release). PR Newswire. December 15, 2011.
  27. ^ Page Module:Citation/CS1/styles.css has no content."Drug Approval Package". Food and Drug Administration.
  28. ^ Page Module:Citation/CS1/styles.css has no content."HIGHLIGHTS OF PRESCRIBING INFORMATION – Prolia (denosumab)" (PDF). Food and Drug Administration. June 2010.
  29. ^ Page Module:Citation/CS1/styles.css has no content."FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury" (Press release). PR Newswire. November 19, 2010.
  30. ^ Page Module:Citation/CS1/styles.css has no content."Amgen to buy Pfizer plant". The Irish Times. March 11, 2011.
  31. ^ Page Module:Citation/CS1/styles.css has no content.Becker, Zoey (June 27, 2022). "Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China". Fierce Pharma. Questex.
  32. ^ Page Module:Citation/CS1/styles.css has no content.Philippidis, Alex (November 1, 2019). "Amgen Expands China Presence, Cancer R&D with $2.7B BeiGene Collaboration". Genetic Engineering and Biotechnology News.
  33. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer". Genetic Engineering and Biotechnology News. November 24, 2014.
  34. ^ Page Module:Citation/CS1/styles.css has no content."Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca". Genetic Engineering and Biotechnology News. November 26, 2014.
  35. ^ Page Module:Citation/CS1/styles.css has no content.Brennan, Zachary (November 21, 2014). "Amgen launches $200m biomanufacturing facility in Singapore". BioPharma-Reporter.
  36. ^ Page Module:Citation/CS1/styles.css has no content.Przepiorka, Donna; Ko, Chia-Wen; Deisseroth, Albert; Yancey, Carolyn L.; Candau-Chacon, Reyes; Chiu, Haw-Jyh; Gehrke, Brenda J.; Gomez-Broughton, Candace; Kane, Robert C.; Kirshner, Susan; Mehrotra, Nitin; Ricks, Tiffany K.; Schmiel, Deborah; Song, Pengfei; Zhao, Ping; Zhou, Qing; Farrell, Ann T.; Pazdur, Richard (September 15, 2015). "FDA Approval: Blinatumomab". Clinical Cancer Research. 21 (18): 4035–4039. doi:10.1158/1078-0432.CCR-15-0612. ISSN 1557-3265. PMID 26374073. S2CID 207687724.
  37. ^ Page Module:Citation/CS1/styles.css has no content."FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia". American Society of Clinical Oncology. December 15, 2014.
  38. ^ Page Module:Citation/CS1/styles.css has no content."Celimmune Licenses Amgen's AMG 714 for Celiac Disease". Genetic Engineering and Biotechnology News. March 2, 2015.
  39. ^ Page Module:Citation/CS1/styles.css has no content.Kolata, Gina (August 27, 2015). "F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class". The New York Times.
  40. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim". Genetic Engineering and Biotechnology News. September 1, 2016.
  41. ^ a b Page Module:Citation/CS1/styles.css has no content.Staton, Tracy (September 23, 2016). "Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market". Fierce Pharma. Questex.
  42. ^ Page Module:Citation/CS1/styles.css has no content.Bell, Jacob (February 8, 2017). "Amgen secures FDA approval for hormone drug". BioPharma Dive. Informa.
  43. ^ a b Page Module:Citation/CS1/styles.css has no content."FDA approves bevacizumab biosimilar Mvasi asi". GaBI Online. September 22, 2017.
  44. ^ Page Module:Citation/CS1/styles.css has no content.Keenan, Joseph (August 1, 2018). "Amgen breaks ground on $200M next-gen biopharma plant in Rhode Island". Fierce Pharma. Questex.
  45. ^ Page Module:Citation/CS1/styles.css has no content."Amgen's New Bio-manufacturing Plant, Rhode Island, US". Pharmaceutical Technology. August 10, 2018.
  46. ^ Page Module:Citation/CS1/styles.css has no content."Evenity gets first ever approval, in Japan". The Pharma Letter. January 9, 2019.
  47. ^ Page Module:Citation/CS1/styles.css has no content.Taylor, Phil (January 9, 2019). "Amgen gets first OK for Evenity in Japan as FDA panel looms". FierceBiotech.
  48. ^ Page Module:Citation/CS1/styles.css has no content.Liu, Angus (April 10, 2019). "Amgen bone drug Evenity finally wins its FDA green light, but there's a catch". Fierce Pharma. Questex.
  49. ^ a b Page Module:Citation/CS1/styles.css has no content."FDA Approves Amgen's Trastuzumab Biosimilar, Kanjinti". The Center For Biosimilars. June 13, 2019.
  50. ^ Page Module:Citation/CS1/styles.css has no content."FDA approves Avsola, fourth Remicade biosimilar". www.healio.com. December 6, 2019.
  51. ^ Page Module:Citation/CS1/styles.css has no content.Astor, Lisa (September 9, 2019). "FDA Grants AMG 510 Fast Track Designation for KRAS G12C+ NSCLC". targetedonc.com.
  52. ^ Page Module:Citation/CS1/styles.css has no content."BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan". Reuters. April 1, 2020.
  53. ^ Page Module:Citation/CS1/styles.css has no content.Liu, Angus (January 23, 2020). "Amgen wades deeper into Asia with full control of an Astellas Japanese JV". Fierce Pharma. Questex.
  54. ^ Page Module:Citation/CS1/styles.css has no content.Stempel, Jonathan (July 1, 2020). Berkrot, Bill; Grebler, Dan (eds.). "Amgen defeats Novartis appeal over arthritis drug Enbrel's patents". Reuters.
  55. ^ Page Module:Citation/CS1/styles.css has no content.Liu, Angus (August 3, 2020). "AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study". Fierce Pharma. Questex.
  56. ^ Page Module:Citation/CS1/styles.css has no content.Blankenship, Kyle (September 17, 2020). "Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails". Fierce Pharma. Questex.
  57. ^ Page Module:Citation/CS1/styles.css has no content.Helwick, Caroline (February 1, 2021). "Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC". American Society of Clinical Oncology.
  58. ^ Page Module:Citation/CS1/styles.css has no content.Ross, Casey (November 10, 2020). "Drug companies deliver a vote of confidence in adaptive trial for Covid-19". STAT.
  59. ^ Page Module:Citation/CS1/styles.css has no content.Beasley, Deena (November 30, 2020). "COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs". Reuters.
  60. ^ Page Module:Citation/CS1/styles.css has no content.Gardner, Jonathan (November 23, 2020). "Amgen cuts Cytokinetics loose after heart drug disappointment". BioPharma Dive.
  61. ^ Page Module:Citation/CS1/styles.css has no content.Dembeck, Lauren (October 18, 2021). "NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma". Pulmonology Advisor.
  62. ^ Page Module:Citation/CS1/styles.css has no content.Taylor, Nick Paul (December 8, 2020). "Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib". FierceBiotech.
  63. ^ a b Page Module:Citation/CS1/styles.css has no content."FDA Approves Riabni, Third Biosimilar to Rituxan". Clinical Oncology News. December 18, 2020.
  64. ^ Page Module:Citation/CS1/styles.css has no content."FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)" (Press release). PR Newswire. December 17, 2020.
  65. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Successfully Completes Acquisition Of Five Prime Therapeutics" (Press release). PR Newswire. April 16, 2021.
  66. ^ Page Module:Citation/CS1/styles.css has no content."Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash". BioSpace. March 4, 2021.
  67. ^ Page Module:Citation/CS1/styles.css has no content.Maddipatla, Manojna (March 4, 2021). "Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market". Reuters.
  68. ^ Page Module:Citation/CS1/styles.css has no content."How Amgen Acquired Five Prime for $1.9 Billion, Beating Out a Dozen Others". BioSpace. March 19, 2021.
  69. ^ Page Module:Citation/CS1/styles.css has no content."In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million". BioSpace. March 31, 2021.
  70. ^ Page Module:Citation/CS1/styles.css has no content."Amgen to Acquire Rodeo Therapeutics Corporation" (Press release). PR Newswire. March 30, 2021.
  71. ^ Page Module:Citation/CS1/styles.css has no content."FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC". American Society of Clinical Oncology. June 25, 2021.
  72. ^ Page Module:Citation/CS1/styles.css has no content.Rosa, Kristi (January 10, 2022). "Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC". Onclive.
  73. ^ Page Module:Citation/CS1/styles.css has no content.Sternberg, Audrey (January 20, 2022). "Sotorasib Earns Approval in Japan for KRAS G12C+ NSCLC". cancernetwork.com.
  74. ^ a b Page Module:Citation/CS1/styles.css has no content."FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC". American Society of Clinical Oncology. June 25, 2021.
  75. ^ Page Module:Citation/CS1/styles.css has no content.Idrus, Amirah Al (June 1, 2021). "Amgen reunites with longtime partner Kyowa Kirin in $400M dermatitis deal". FierceBiotech.
  76. ^ Page Module:Citation/CS1/styles.css has no content.Taylor, Nick Paul (October 7, 2021). "Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D". FierceBiotech.
  77. ^ Page Module:Citation/CS1/styles.css has no content.Mishra, Manas (October 7, 2021). Kuber, Shailesh (ed.). "Amgen to invest $100 million in SoftBank-backed Neumora". Reuters.
  78. ^ Page Module:Citation/CS1/styles.css has no content."Amgen breaks ground on new biomanufacturing facility in Ohio, US". NS Healthcare. November 8, 2021.
  79. ^ a b Page Module:Citation/CS1/styles.css has no content.Dunleavy, Kevin (December 20, 2021). "Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspire". Fierce Pharma. Questex.
  80. ^ Page Module:Citation/CS1/styles.css has no content.Nadeem, Dania (December 20, 2021). M., Ramakrishnan (ed.). "U.S. FDA approves expanded use of Amgen's psoriasis drug". Reuters.
  81. ^ Page Module:Citation/CS1/styles.css has no content.Armstrong, Annalee (January 6, 2022). "Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs". FierceBiotech.
  82. ^ Page Module:Citation/CS1/styles.css has no content.Philippidis, Alex (January 6, 2022). "Amgen, Generate Launch Up-to-$1.9B Protein Therapeutics Collaboration". Genetic Engineering and Biotechnology News.
  83. ^ Page Module:Citation/CS1/styles.css has no content.Armstrong, Annalee (January 11, 2022). "JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal". FierceBiotech.
  84. ^ Page Module:Citation/CS1/styles.css has no content.Pagliarulo, Ned (January 11, 2022). "Amgen partners with Arrakis to develop drugs aimed at RNA". BioPharma Dive. Informa.
  85. ^ Page Module:Citation/CS1/styles.css has no content.Shasteen, Hayley (February 3, 2022). "Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact". BioSpace.
  86. ^ Page Module:Citation/CS1/styles.css has no content.LaHucik, Kyle (February 3, 2022). "Amgen enters hot protein degradation field with $500M biobucks deal with Plexium". FierceBiotech.
  87. ^ Page Module:Citation/CS1/styles.css has no content.Pequeño IV, Antonio (February 23, 2022). "Amgen Issues 'Green Bond'". San Fernando Valley Business Journal.
  88. ^ Page Module:Citation/CS1/styles.css has no content.Mutua, David Caleb (March 29, 2022). "Amgen Mulls More Green Bonds After 'Robust Interest' in Debut". Bloomberg News.
  89. ^ Page Module:Citation/CS1/styles.css has no content.Parker, Jason (March 7, 2022). "Amgen expects new Holly Springs plant to be 'a permanent home'". WRAL-TV.
  90. ^ Page Module:Citation/CS1/styles.css has no content.Sterling, John (March 11, 2022). "Amgen Breaks Ground on NC Biomanufacturing Facility". Genetic Engineering and Biotechnology News.
  91. ^ Page Module:Citation/CS1/styles.css has no content.Walker, Joseph (September 12, 2022). "New Cancer Drug Beats Chemotherapy in Study". The Wall Street Journal. ISSN 0099-9660.
  92. ^ Page Module:Citation/CS1/styles.css has no content.Walker, Joseph (August 4, 2022). "Amgen to Buy ChemoCentryx for $3.7 Billion". The Wall Street Journal.
  93. ^ Page Module:Citation/CS1/styles.css has no content."AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX" (Press release). PR Newswire. October 20, 2022.
  94. ^ Page Module:Citation/CS1/styles.css has no content.Chen, I-Chun (October 21, 2022). "Amgen completes purchase of ChemoCentryx for $3.7 billion". American City Business Journals.
  95. ^ Page Module:Citation/CS1/styles.css has no content."Amgen completes $27.8 billion Horizon deal". Reuters. October 6, 2023.
  96. ^ Page Module:Citation/CS1/styles.css has no content.Mishra, Manas; Satija, Bhanvi (December 12, 2022). "Amgen dives deeper into rare disease drugs with $27.8 BLN Horizon deal". Reuters.
  97. ^ Page Module:Citation/CS1/styles.css has no content."AWS Joins Forces With Amgen on Generative AI Solutions to Accelerate Advanced Therapies" (Press release). Business Wire. November 28, 2023.
  98. ^ Page Module:Citation/CS1/styles.css has no content.Liu, Angus (March 3, 2025). "Amgen, AZ Tezspire sinusitis data invite 'best-in-disease' talk". Fierce Pharma. Questex.
  99. ^ Page Module:Citation/CS1/styles.css has no content.Garde, Damian (March 5, 2025). "Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug". Bloomberg News.
  100. ^ Page Module:Citation/CS1/styles.css has no content.Constantino, Annika Kim (March 5, 2025). "Amgen starts two critical late-stage trials for weight loss drug MariTide". CNBC.
  101. ^ Page Module:Citation/CS1/styles.css has no content.Beasley, Deena (June 24, 2025). Berkrot, Bill (ed.). "Amgen experimental weight-loss drug needs lower dose to limit side effects". Reuters.
  102. ^ Page Module:Citation/CS1/styles.css has no content.Chen, Elaine (June 23, 2025). "Amgen's obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing". Stat.
  103. ^ Page Module:Citation/CS1/styles.css has no content.Ghose, Carrie (April 25, 2025). "Amgen to invest $900 million in New Albany expansion, nearly doubling job creation". American City Business Journals.
  104. ^ Page Module:Citation/CS1/styles.css has no content.Biasotti, Tony (September 3, 2025). "Amgen to build $600M research center in Thousand Oaks". Ventura County Star.
  105. ^ Page Module:Citation/CS1/styles.css has no content.Olmos, David (November 19, 1994). "Amgen to Acquire Synergen in $239-Million Biotech Deal". Los Angeles Times.
  106. ^ Page Module:Citation/CS1/styles.css has no content.Murphy, Barbara (October 24, 2000). "Amgen Agrees to Buy Drug Maker Kinetix". Los Angeles Times.
  107. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Agrees to Acquire Biotech Company Avidia". The Wall Street Journal. September 29, 2006.
  108. ^ Page Module:Citation/CS1/styles.css has no content."Amgen to Acquire Alantos Pharmaceuticals". Technology Networks. June 8, 2007.
  109. ^ Page Module:Citation/CS1/styles.css has no content."Amgen to Acquire Ilypsa for $420M". Genetic Engineering and Biotechnology News. June 5, 2007.
  110. ^ Page Module:Citation/CS1/styles.css has no content."Medigene AG: Amgen acquires Medigene spin-off Catherex". FierceBiotech. December 21, 2015.
  111. ^ Page Module:Citation/CS1/styles.css has no content.Erman, Michael; Mishra, Manas (August 26, 2019). "Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion". Reuters.
  112. ^ Page Module:Citation/CS1/styles.css has no content.Adams, Ben (March 4, 2021). "Prime time for Five Prime as Amgen snaps up this once-moribund biotech for $1.9B and its phoenix-from-the-flames cancer asset". FierceBiotech.
  113. ^ Page Module:Citation/CS1/styles.css has no content.Idrus, Amirah Al (March 30, 2021). "Amgen saddles up with Rodeo for a $55M trek into regenerative medicine". FierceBiotech.
  114. ^ Page Module:Citation/CS1/styles.css has no content.Philippidis, Alex (August 5, 2022). "Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio". Genetic Engineering and Biotechnology News.
  115. ^ Page Module:Citation/CS1/styles.css has no content.Bell, Jacob; Fidler, Ben (February 1, 2021). "Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca". Biopharma Dive. Informa.
  116. ^ Page Module:Citation/CS1/styles.css has no content."Irish Open sponsor name change after Amgen's takeover of Horizon". Irish Independent. December 14, 2023.
  117. ^ Page Module:Citation/CS1/styles.css has no content.Vuocolo, Alex (June 23, 2020). "Khan Academy Founder Says $3M Grant Will Help Tackle Inequities in Virtual Education". Cheddar.
  118. ^ Page Module:Citation/CS1/styles.css has no content.D'Angelo, Alexa (October 29, 2017). "Amgen Foundation awards Khan Academy $3 million to support development of biology". Ventura County Star.
  119. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Foundation awards $3 million to Khan Academy". Candid. July 24, 2020.
  120. ^ Page Module:Citation/CS1/styles.css has no content.Molina, Brett (July 30, 2020). "Q&A: Khan Academy CEO Sal Khan on the new school year and virtual learning". USA Today.
  121. ^ Page Module:Citation/CS1/styles.css has no content.Kelly, Rhea (January 24, 2020). "Amgen and Harvard Launch Free Online Science Ed Platform -- Campus Technology". Campus Technology.
  122. ^ Page Module:Citation/CS1/styles.css has no content.Kahn, Natalie L.; Wang, Andy Z. (April 8, 2020). "Harvard's LabXChange Provides Platform for Remote Scientific Learning During Pandemic". The Harvard Crimson.
  123. ^ Page Module:Citation/CS1/styles.css has no content."Amgen, AT&T, Others Announce Commitments for COVID-19 Response". Candid. March 25, 2020.
  124. ^ Page Module:Citation/CS1/styles.css has no content."CDC Foundation Active Programs October 1, 2020 – September 30, 2021". CDC Foundation. December 9, 2021. Archived from the original on January 15, 2022.
  125. ^ Page Module:Citation/CS1/styles.css has no content.Raedler, Lisa A. (April 15, 2019). "Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults". American Health & Drug Benefits. 12.
  126. ^ Page Module:Citation/CS1/styles.css has no content.Pollack, Andrew (September 19, 2001). "F.D.A. Approves New Version of Amgen Drug". The New York Times.
  127. ^ Food and Drug Administration December 3, 2014 FDA Press release: Blinatumomab
  128. ^ Page Module:Citation/CS1/styles.css has no content.Berkrot, Bill (October 27, 2015). "FDA approves Amgen's injected immunotherapy for melanoma". Reuters.
  129. ^ Page Module:Citation/CS1/styles.css has no content."FDA approves Amgen's new-generation filgrastim product, Neulasta". www.thepharmaletter.com. November 2, 2002.
  130. ^ Page Module:Citation/CS1/styles.css has no content.Heavey, Susan (August 22, 2008). "U.S. FDA approves Amgen's blood platelet booster". Reuters.
  131. ^ Page Module:Citation/CS1/styles.css has no content.Jamali, Faranak; Lemery, Steven; Ayalew, Kassa; Robottom, Suzanne; Robie-Suh, Kathy; Rieves, Dwaine; Pazdur, Richard (July 2009). "Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura". Oncology (Williston Park, N.Y.). 23 (8): 704–709. ISSN 0890-9091. PMID 19711585.
  132. ^ Page Module:Citation/CS1/styles.css has no content.Jeffries, Fleur (March 28, 2022). "Amgen shares new Otezla data at American Academy of Dermatology congress 2022". PMLive.
  133. ^ Page Module:Citation/CS1/styles.css has no content."New FDA Approvals". clinician.com. May 1, 2004.
  134. ^ Page Module:Citation/CS1/styles.css has no content."Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688". U.S. Food and Drug Administration. Archived from the original on February 18, 2013.
  135. ^ Page Module:Citation/CS1/styles.css has no content.Giusti, Ruthann M.; Shastri, Kaushikkumar A.; Cohen, Martin H.; Keegan, Patricia; Pazdur, Richard (May 2007). "FDA drug approval summary: panitumumab (Vectibix)". The Oncologist. 12 (5): 577–583. doi:10.1634/theoncologist.12-5-577. ISSN 1083-7159. PMID 17522246. S2CID 9376408.
  136. ^ a b c Page Module:Citation/CS1/styles.css has no content."Biovitrum and Amgen Announce Close of Product Acquisition Deal" (Press release). GlobeNewswire. December 16, 2008.
  137. ^ Page Module:Citation/CS1/styles.css has no content.Terhune, Chad (December 18, 2012). "Amgen pleads guilty to improper marketing of anemia drug Aranesp". Los Angeles Times.
  138. ^ Page Module:Citation/CS1/styles.css has no content."Amgen Inc. Pleads Guilty to Federal Charge in Brooklyn, NY.;Pays $762 Million to Resolve Criminal Liability and False Claims Act Allegations" (Press release). United States Department of Justice. December 19, 2012.
  139. ^ Page Module:Citation/CS1/styles.css has no content.Brittain, Blake (May 15, 2025). Osterman, Cynthia (ed.). "Amgen owes $406 million for monopolizing cholesterol drug market, US jury says". Reuters.

Page Module:Side box/styles.css has no content.Page Template:Sister project/styles.css has no content.

Page Template:Plainlist/styles.css has no content.
Script error: No such module "Sister project logo".
Wikimedia Commons has media related to [[commons:Template:If then show|Template:If then show]].

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:NASDAQ-100 Template:S&P 500 companies Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Amgen&oldid=554532"